InMed Pharmaceuticals Inc.

INMReported to SECin USCIK 0001728328Filings at SEC EDGAR

No score on this page, by design. Everything here is a fact from a public U.S. register: insider filings at the SEC (Form 4), lobbying filings under the Lobbying Disclosure Act, trades reported by members of Congress under the STOCK Act, and fund holdings in 13F filings. Our scores, percentiles and signals run on the Dutch register only, because that is the only register the model has been validated on.

This page is free to read, and it stops after 5 rows. Those are the 5 most recent Form 4 lines at this company, out of 16. Reading the whole list, and the full version of each filer's page, is part of the subscription. What that costs is on the pricing page. Already subscribed? Sign in and this page opens in full.

The most recent filings

Most recent filing first: every line of every Form 4 at this company that passed our review, the same lines as on the register. Reported is the day the filing reached the SEC, usually within two business days of the trade. Amounts are in U.S. dollars, as the form states them.

5 of 16
Form 4 lines at InMed Pharmaceuticals Inc., most recent filing first
Filed byTypeValueReportedFiled byValueTypeSharesReported
ADAR1 Capital Management, LLC—Open-market buy$10,7508,340 sharesSep 16, 2026ADAR1 Capital Management, LLC$10,750Buy · Sep 16Open-market buy8,340Sep 16, 2026
ADAR1 Capital Management, LLC—Open-market buy$70,44654,256 sharesSep 16, 2026ADAR1 Capital Management, LLC$70,446Buy · Sep 16Open-market buy54,256Sep 16, 2026
ADAR1 Capital Management, LLC—Open-market buy$36,88028,505 sharesSep 16, 2026ADAR1 Capital Management, LLC$36,880Buy · Sep 16Open-market buy28,505Sep 16, 2026
ADAR1 Capital Management, LLC—Open-market buy$1,5551,000 sharesJul 17, 2026ADAR1 Capital Management, LLC$1,555Buy · Jul 17Open-market buy1,000Jul 17, 2026
Vivo Opportunity, LLC—Open-market buy$32 sharesJul 16, 2026Vivo Opportunity, LLC$3Buy · Jul 16Open-market buy2Jul 16, 2026